Who are Replimune Group, Inc.'s main suppliers?

Replimune Group, Inc. (REPL) key suppliers include: ROCHE, Genelux Corporation. View the full supplier network at chainsifter.com/chain/REPL.

Who are Replimune Group, Inc.'s major customers?

Replimune Group, Inc. (REPL) key customers include: Genelux Corporation, Intensity Therapeutics, Inc.. View the full customer network at chainsifter.com/chain/REPL.

What sector is Replimune Group, Inc. in?

Replimune Group, Inc. (REPL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

REPL Supply Chain: Replimune Group, Inc. Suppliers & Customers

2Suppliers

2Customers

3Debt Items

20Related Chains

Replimune Group, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ROCHE	ROCHE	90%	The ongoing study in HCC is being developed in combination with atezolizumab and bevacizumab under a supply and clinical collaboration agreement with Roche.
GNLX	Genelux Corporation	72%	Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, producti…

Replimune Group, Inc. Customers

Ticker	Name	Confidence	Evidence
GNLX	Genelux Corporation	72%	Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, producti…
INTS	Intensity Therapeutics, Inc.	72%	Reciprocal relationship from INTS graph: n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The government may …

Replimune Group, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
REPL-DEBT-12132	Warrants outstanding: 5284238	90%	xbrl warrant detail from xbrl 2022-03-31.
REPL-DEBT-12133	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-03-31.
REPL-DEBT	Debt stack $76.3M	90%	Market cache reports total debt of $76.3M.

Replimune Group, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Replimune Group, Inc..

Replimune Group, Inc. Ownership

Holder	Name	Confidence	Evidence
REPL-OWNER-BAKER-BROS-ADVISORS-LP	BAKER BROS. ADVISORS LP	90%	13F overlay lists BAKER BROS. ADVISORS LP as top holder; 187 tracked holders.

Replimune Group, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ALEC	Alector, Inc.	100.00	2
CLLS	Cellectis S.A.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CMPS	COMPASS Pathways plc	100.00	2
TLSA	Tiziana Life Sciences Ltd	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
BCYC	Bicycle Therapeutics plc	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
ATON	AlphaTON Capital Corp	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
IRON	Disc Medicine, Inc.	100.00	2
SVRA	Savara Inc.	100.00	2
ALT	Altimmune, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
GNLX	Genelux Corporation	100.00	1	['customer', 'supplier']

Replimune Group, Inc. Supply Chain